Current price is more than the intrinsic value

Intrinsic Value

Stock has not been able to generate better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Prabhudas Lilladher recommended accumulate rating on Indoco Remedies with a target price of Rs 480 in its research report dated November 04, 2021.

Accumulate Indoco Remedies; Target Of Rs 480: Prabhudas Lilladher

Indoco Remedies consolidated net profit rises 62.53% in the September 2021 quarter

For trade in Nifty, we advise traders to wait for the prices to dip towards 18,100 –18,000 to initiate a fresh long position for an appropriate risk-reward ratio, said Rohan Patil of Bonanza Portfolio

Hot Stocks | Here Is Why You Should Buy Indoco Remedies, Jindal Steel And Apollo Pipes For The Short Term

Indoco Remedies Ltd, Balmer Lawrie & Company Ltd, Union Bank of India and Network 18 Media & Investments Ltd are among the other gainers in the BSE’s ‘A’ group today, 20 October 2021.

Transport Corporation of India Ltd leads gainers in ‘A’ group

Net Sales are expected to increase by 24.2 percent Y-o-Y (up 5.1 percent Q-o-Q) to Rs 400.5 crore, according to Prabhudas Lilladher.

Indoco Remedies Q2 PAT Seen Up 53.9% YoY To Rs 38.6 Cr: Prabhudas Lilladher

Indoco Remedies Management Meet Update - Outlook Remains Strong: Nirmal Bang

Indoco Remedies Ltd clocked volume of 34.4 lakh shares by 14:19 IST on NSE, a 10.83 times surge over two-week average daily volume of 3.18 lakh shares

Volumes soar at Indoco Remedies Ltd counter

Action Construction Equipment Ltd, Tata Coffee Ltd, Brigade Enterprises Ltd and Indian Energy Exchange Ltd are among the other gainers in the BSE’s ‘A’ group today, 31 August 2021.

Indoco Remedies Ltd leads gainers in ‘A’ group

Drug firm Indoco Remedies CRO arm gets UK MHRA accreditation

Indoco Remedies rose 0.7% to Rs 450.8 after the drug maker said it received GCP & GLP accreditation from the UK drug regulator for its clinical research organisation, AnaCipher, in Hyderabad.

Indoco Remedies rises after AnaCipher gets UKMHRA accreditation

Indoco Remedies receives UKMHRA accreditation for its clinical research facility at Hyderabad

Indoco Remedies Limited is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

Indoco Remedies Ltd

Indoco Remedies Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Accumulate Indoco Remedies; Target Of Rs 480: Prabhudas Lilladher

Indoco Remedies consolidated net profit rises 62.53% in the September 2021 quarter

Hot Stocks | Here Is Why You Should Buy Indoco Remedies, Jindal Steel And Apollo Pipes For The Short Term

Transport Corporation of India Ltd leads gainers in ‘A’ group

Indoco Remedies Q2 PAT Seen Up 53.9% YoY To Rs 38.6 Cr: Prabhudas Lilladher

Indoco Remedies Management Meet Update - Outlook Remains Strong: Nirmal Bang

Volumes soar at Indoco Remedies Ltd counter

Indoco Remedies Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Accumulate Indoco Remedies; Target Of Rs 480: Prabhudas Lilladher

Indoco Remedies consolidated net profit rises 62.53% in the September 2021 quarter

Hot Stocks | Here Is Why You Should Buy Indoco Remedies, Jindal Steel And Apollo Pipes For The Short Term

Transport Corporation of India Ltd leads gainers in ‘A’ group

Indoco Remedies Q2 PAT Seen Up 53.9% YoY To Rs 38.6 Cr: Prabhudas Lilladher

Indoco Remedies Management Meet Update - Outlook Remains Strong: Nirmal Bang

Volumes soar at Indoco Remedies Ltd counter

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock